Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial
Alimentary Pharmacology & Therapeutics · 2026-08 · 64 (4) · 458-470
DOI: 10.1111/apt.70811 ↗At a glance
Randomisierte kontrollierte Studie in Alimentary Pharmacology & Therapeutics, published online on 2026-07-07. Written by Rino Alvani Gani and 7 co-authors. Institution: Hepatobiliary Division, Internal Medicine Department, Dr Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia, Jak…. Major MEDLINE topics: Liver Cirrhosis, Pyridines, Pyrimidines, Sleep Initiation and Maintenance Disorders. Cited 4 times so far (Crossref); 25 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Eisai Indonesia.
Abstract (original language)
Background and Aim No pharmacologic treatment has yet been approved for sleep disturbances in cirrhosis, a high‐risk group with substantial prevalence and clinical consequences. Lemborexant has shown efficacy for insomnia, but evidence in cirrhosis is limited.
Methods
Restoring Sleep in End‐Stage Liver Disease (RESTORE) is a prospective, double‐blind, placebo‐controlled, crossover trial of Lemborexant for patients with cirrhosis in Cipto Mangunkusumo National Referral Hospital. We randomized 82 patients into three arms: Placebo ( n = 28), 5 mg Lemborexant ( n = 28), and 10 mg Lemborexant ( n = 26). Efficacy was assessed via Pittsburgh Sleep Quality Index (PSQI) over a 2‐week period. Safety was evaluated using the EncephalApp Stroop Test for hepatic encephalopathy and liver function tests including AST, ALT, and total bilirubin. PSQI was reevaluated post‐crossover at week 4 to investigate rebound insomnia.
Results
Lemborexant significantly reduced PSQI at week 2 in both 5 mg (MD: −7.0 ± 3.15; p < 0.001) and 10 mg groups (MD: −8.27 ± 2.68; p < 0.001), indicating better sleep quality. The 5 mg group showed improved Stroop Test reaction time (MD: −23.5 ± 31.3; p < 0.001), suggesting better cognitive function, whereas 10 mg showed a mild but significant increase in reaction time (MD: 16.7 ± 41.3; p = 0.048). Liver function was not different across treatment groups. Post‐crossover analysis showed persistent low PSQI scores in active groups who were switched to placebo. Patients who initially received placebo demonstrated improved sleep after receiving Lemborexant.
Conclusion
Our study supported the efficacy and safety of Lemborexant, particularly at 5 mg, against sleep problems in cirrhosis. Larger studies with longer follow‐up are warranted to strengthen evidence. ClinicalTrials.gov: NCT07480096.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Hepatobiliary Division, Internal Medicine Department, Dr Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
ORCID profiles: Rino Alvani Gani, Pitt Akbar, Irsan Hasan, Andri Sanityoso Sulaiman, Cosmas Rinaldi Adithya Lesmana, Juferdy Kurniawan, Valerie Josephine Dirjayanto
Funding
- Eisai Indonesia
Cite
APA
Gani, R. A., Akbar, P., Hasan, I., Sulaiman, A. S., Lesmana, C. R. A., Kurniawan, J., Panjaitan, S. M., & Dirjayanto, V. J. (2026). Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial. Alimentary Pharmacology & Therapeutics, 64(4), 458-470. https://doi.org/10.1111/apt.70811
Vancouver
Gani RA, Akbar P, Hasan I, Sulaiman AS, Lesmana CRA, Kurniawan J, et al. Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial. Alimentary Pharmacology & Therapeutics. 2026;64(4):458-470. doi:10.1111/apt.70811
BibTeX
@article{Gani2026,
author = {Gani, Rino Alvani and Akbar, Pitt and Hasan, Irsan and Sulaiman, Andri Sanityoso and Lesmana, Cosmas Rinaldi Adithya and Kurniawan, Juferdy and Panjaitan, Sarah Melissa and Dirjayanto, Valerie Josephine},
title = {Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis—Randomized, Double‐Blind, Crossover Clinical Trial},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {64},
number = {4},
pages = {458--470},
doi = {10.1111/apt.70811}
}
EUVIMED